Publicacións en colaboración con investigadores/as de Hospital Universitario La Paz (42)

2024

  1. Clinical Characteristics of Patients With Acquired Partial Lipodystrophy: A Multicenter Retrospective Study

    The Journal of clinical endocrinology and metabolism, Vol. 109, Núm. 3, pp. e932-e944

2023

  1. Cardiogenic shock code 2023. Expert document for a multidisciplinary organization that allows quality care

    Revista Espanola de Cardiologia, Vol. 76, Núm. 4, pp. 261-269

  2. Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: The EDICA trial

    International Journal of Cardiology, Vol. 391

  3. Characterization and Clinical Association of Autoantibodies Against Perilipin 1 in Patients With Acquired Generalized Lipodystrophy

    Diabetes, Vol. 72, Núm. 1, pp. 71-84

  4. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension

    European Journal of Heart Failure, Vol. 25, Núm. 7, pp. 936-955

2022

  1. Clinical and therapeutic characterization of the ischemic cardiopathy in Spain. Importance of cardiac rehabilitation programs

    Medicina Clinica Practica, Vol. 5, Núm. 3

  2. The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: The NEPTUNO study

    International Journal of Cardiology, Vol. 361, pp. 116-123

2021

  1. Complement factor d (Adipsin) levels are elevated in acquired partial lipodystrophy (barraquer–simons syndrome)

    International Journal of Molecular Sciences, Vol. 22, Núm. 12

  2. Lipid lowering treatment in patients with very high risk cardiovascular disease. Spanish Society of Cardiology Consensus Document for the use of PCSK9 inhibitors in clinical practice

    REC: CardioClinics, Vol. 56, Núm. 1, pp. 39-48

2020

  1. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry

    European heart journal, Vol. 41, Núm. 18, pp. 1720-1729

  2. Correction: Immunological features of patients affected by Barraquer-Simons syndrome (Orphanet Journal of Rare Diseases DOI: 10.1186/s13023-019-1292-1)

    Orphanet Journal of Rare Diseases

  3. Evidence of ongoing complement activation on adipose tissue from an 11-year-old girl with Barraquer–Simons syndrome

    Journal of Dermatology, Vol. 47, Núm. 12, pp. 1439-1444

  4. Immunological features of patients affected by Barraquer-Simons syndrome

    Orphanet Journal of Rare Diseases, Vol. 15, Núm. 1

2018

  1. Autoantibodies against perilipin 1 as a cause of acquired generalized lipodystrophy

    Frontiers in Immunology, Vol. 9, Núm. SEP

  2. Exercise-related severe cardiac events

    Scandinavian Journal of Medicine and Science in Sports, Vol. 28, Núm. 4, pp. 1404-1411

  3. Long-term prognosis of patients with life-threatening ventricular arrhythmias induced by coronary artery spasm

    Europace, Vol. 20, Núm. 5, pp. 851-858

2017

  1. A Brief History. Impact of the Advances in Ischaemic Heart Disease

    Revista Espanola de Cardiologia Suplementos, Vol. 17, pp. 2-6

  2. Réplica a «Tratamiento de la hiperuricemia asintomática»

    Revista Clinica Espanola

2016

  1. La ecografía en el diagnóstico de la hiperuricemia asintomática y la gota

    Revista Clinica Espanola

  2. Necesidades no cubiertas con el tratamiento hipolipemiante oral: documento de posición de la Sociedad Española de Cardiología

    Revista Espanola de Cardiologia, Vol. 69, Núm. 11, pp. 1083-1087